Moreover, IL-6 −174 G/G genotype was associated with better response to anti-TNF agent (infliximab, adalimumab, etanercept) and anti-CD20 rituximab (Table 2), suggesting that a pharmacogenetic pre-evaluation of patients could be useful for a targeted treatment of RA patients. Here, IL6 is linked to rheumatoid arthritis.